Anti-Cytokeratin 7 Alexa Fluor® 488

*van Niekerk CC, Boerman OC, Ramaekers FC, Poels LG: Marker profile of different phases in the transition of normal human ovarian epithelium to ovarian carcinomas. Am J Pathol. 1991 Feb;138 (2) :455-63., URL: https://pubmed.ncbi.nlm.nih.gov/1992770/, *Torenbeek R, Lagendijk JH, Van Diest PJ, Bril H, van de Molengraft FJ, Meijer CJ: Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma. Histopathology 1998 Jan;32 (1) :20-7. , URL: https://pubmed.ncbi.nlm.nih.gov/9522212/, *van Niekerk CC, Vooijs P, Casparie-van Velsen IJ, Poels LG: Differentiation margins of ovarian tumor pathology: First incidences of epithelial ovarian tumors monitored by marker antibodies. Cancer Detect Prev. 1997;21 (3) :247-57., URL: https://pubmed.ncbi.nlm.nih.gov/9167042/, *van Niekerk CC, Jap PH, Ramaekers FC, van de Molengraft F, Poels LG: Immunohistochemical demonstration of keratin 7 in routinely fixed paraffin-embedded human tissues. J Pathol. 1991 Oct;165 (2) :145-52. , URL: https://pubmed.ncbi.nlm.nih.gov/1720817/, *Ramaekers F, van Niekerk C, Poels L, Schaafsma E, Huijsmans A, Robben H, Schaart G, Vooijs P: Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas. Am J Pathol. 1990 Mar;136 (3) :641-55., URL: https://pubmed.ncbi.nlm.nih.gov/1690512/